ng days and 190 mg. of naltrexone resulted in a 17 percent decrease. Sex and pretreatment abstinence each showed significant interaction with the medication group on treatment outcome, with men and those with lead-in abstinence both exhibiting greater treatment effects. Discontinuation due to adverse events (e.g. nausea, headache, fatigue) occurred in 14.1 percent in the 380-mg. and 6.7 percent in the 190-mg. group and 6.7 percent in the placebo group. Overall, rate and time to treatment discontinuation were similar among treatment groups.

"In summary, the results from this trial, with one of the largest samples ever treated with a medication for alcohol dependence, indicate that long-acting injectable naltrexone is well tolerated and is associated with a significant reduction in heavy drinking in a population of actively drinking patients. The long-acting formulation has the potential to improve intervention strategies for alcohol dependence by providing a predictable pharmacological foundation for treatment. In addition to their utility for alcohol dependence, long-acting formulations may prove to be an important treatment strategy for a variety of addictive disorders," the authors write.

'"/>

Contact: Stephanie Crayton
919-966-2860
JAMA and Archives Journals
5-Apr-2005

Page: 1 2
Related medicine news :

1. Once-a-month naltrexone successfully used to treat alcohol dependence
2. New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate
3. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
4. Adding medication improves recovery for elderly with depression, says Pitt School of Medicine study
5. Heart failure medication does not improve survival, compared to more widely used medication
6. Commonly used pain medications do not prevent Alzheimers disease
7. Standard long-acting insulin as good as newer medications
8. MS patients not receiving medications to slow disease progression, research shows
9. Study sheds light on medication treatment options for bipolar disorder
10. Landmark schizophrenia treatment study reveals that medication alone is not always effective
11. Cost control measures limit patient and physician choice in psychotropic medications